0000000000177853

AUTHOR

Patrick Maisonneuve

0000-0002-5309-4704

showing 10 related works from this author

Relation of childhood brain tumors to exposure of parents and children to tobacco smoke: The Search international case-control study

2002

The etiology of childhood brain tumors (CBTs) remains unknown. Tobacco smoke contains several known carcinogens and can induce DNA adducts in human placenta and hemoglobin adducts in fetuses. We present the results of an international case-control study to evaluate the association between CBTs and exposure of parents and children to cigarette smoke. The study was undertaken as part of the SEARCH program of the IARC. Nine centers in 7 countries were involved. The studies mainly covered the 1980s and early 1990s. Cases (1,218, ages 0-19 years) were children newly diagnosed with a primary brain tumor; there were 2,223 population-based controls. Most mothers who agreed to participate were inter…

Cancer ResearchPediatricsmedicine.medical_specialtyPregnancyeducation.field_of_studyPassive smokingbusiness.industryPopulationCase-control studyOdds ratiomedicine.disease_causemedicine.diseaseTobacco smokeOncologyEpidemiologymedicineRisk factorbusinesseducationInternational Journal of Cancer
researchProduct

Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population.

2016

Background & Aims: Life expectancy of patients with compensated hepatitis C virus (HCV) cirrhosis achieving sustained virologic response (SVR) is limited by liver events as compared to the general population. Thus, survival benefit of SVR remains to be measured. Methods: The study includes prospective surveillance data from three cohorts of Italian patients with compensated HCV cirrhosis who achieved SVR on an interferon-based (IFN) regimen, compared to simultaneously observed non-SVR, untreated and decompensated patients. Overall survival was calculated from the date of start of IFN to death. The number of deaths expected during the at-risk period was determined by applying age- and se…

AdultLiver CirrhosisMalemedicine.medical_specialtySustained Virologic ResponsePopulation03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansProspective StudieseducationSurvival analysisAgededucation.field_of_studyHepatologybusiness.industryMortality rateHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseSurgerySurvival RateRegimenStandardized mortality ratio030220 oncology & carcinogenesisRelative riskHCVFemale030211 gastroenterology & hepatologyInterferonsViral hepatitisbusiness
researchProduct

Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological re…

2017

Background Few studies examined the outcome of patients with hepatitis C virus (HCV)-related cirrhosis who developed hepatocellular carcinoma (HCC). The relative weight as determinant of death for cancer vs end-stage liver disease (ESLD) and the benefit of HCV eradication remain undefined. This multicentre, retrospective analysis evaluates overall survival (OS), rate of decompensation and tumour recurrence in compensated HCC patients treated with interferon (IFN) according to HCV status since HCC diagnosis. Methods Two groups of patients with HCV-related cirrhosis and HCC were followed since HCC diagnosis: (i) compensated cirrhotics with prior sustained virological response (SVR) on IFN-bas…

Liver CirrhosisMaleCirrhosisTime FactorsSustained Virologic ResponseHepacivirusKaplan-Meier Estimatemedicine.disease_causeGastroenterologyLiver disease0302 clinical medicineRisk Factorshepatitis C viruLiver Neoplasmsvirus diseasesHepatitis Chepatocellular carcinomainterferonMiddle AgedHepatitis CTreatment OutcomeItaly030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyDrug Therapy CombinationFemalesustained virological responseLiver cancermedicine.medical_specialtyCarcinoma HepatocellularHepatitis C virussurvivalAntiviral Agents03 medical and health sciencesInternal medicineRibavirinmedicinehepatitis C virus; hepatocellular carcinoma; interferon; survival; sustained virological response; HepatologyHumansDecompensationPropensity ScoreAgedProportional Hazards ModelsRetrospective StudiesHepatologybusiness.industryHepatologymedicine.diseasedigestive system diseasesMultivariate AnalysisInterferonsNeoplasm Recurrence LocalbusinessLiver international : official journal of the International Association for the Study of the Liver
researchProduct

High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma

2018

Background: The efficacy of direct-acting anti-viral (DAA) therapy in patients with a history of hepatocellular carcinoma (HCC) is unknown. Aim: We prospectively evaluated whether previously treated HCC affects DAA efficacy in a large real-life cohort of cirrhotic patients. Methods: From January to December 2015 all consecutive HCV mono-infected patients with cirrhosis and/or history of HCC attending 10 Italian tertiary liver centres were enrolled. Baseline characteristics and response to therapy were recorded. 1927 patients were enrolled (mean age: 62.1 10.9 years; 1.205 males). Genotype 1 was the most frequent (67.9%) followed by genotypes 3 (12.4%), 2 (11.2%) and 4 (8.6%). 88.4% and 10.9…

Liver CirrhosisMaleSimeprevirPyrrolidinesSustained Virologic ResponseSofosbuvirHepacivirusAged; Antiviral Agents; Benzimidazoles; Carcinoma Hepatocellular; Cohort Studies; Drug Therapy Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatic Encephalopathy; Hepatitis C Chronic; Humans; Imidazoles; Interferons; Italy; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphatemedicine.disease_causeGastroenterologyCohort Studieschemistry.chemical_compound0302 clinical medicineSimeprevirPharmacology (medical)Prospective Studies030212 general & internal medicineChronicLiver NeoplasmsImidazolesGastroenterologyValineHepatitis CMiddle AgedHepatitis CItalyHepatocellular carcinomaCombinationHCVDrug Therapy CombinationFemale030211 gastroenterology & hepatologyUridine Monophosphatemedicine.drugLedipasvirmedicine.medical_specialtyCarcinoma HepatocellularDaclatasvirGenotypeHepatitis C virusAntiviral Agents03 medical and health sciencesDrug TherapyInternal medicineRibavirinmedicineHumansAgedFluorenesHepatologybusiness.industryCarcinomaHepatocellularHepatitis C Chronicmedicine.diseasedigestive system diseasesRegimenchemistryHepatic EncephalopathyBenzimidazolesCarbamatesInterferonsSofosbuvirbusinessAlimentary Pharmacology & Therapeutics
researchProduct

Mortality risk according to different clinical characteristics of first episode of liver decompensation in cirrhotic patients: a nationwide, prospect…

2013

Abstract OBJECTIVES: The occurrence of decompensation marks a crucial turning point in the course of cirrhosis. The purpose of this study was to assess the risk of mortality according to the clinical characteristics of first decompensation, considering also the impact of acute-on-chronic liver failure (AoCLF). METHODS: We conducted a prospective nationwide inception cohort study in Italy. Decompensation was defined by the presence of ascites, either overt or detected by ultrasonography (UD), gastroesophageal variceal bleeding (GEVB), and hepatic encephalopathy (HE). AoCLF was defined according to the Asian Pacific Association for the Study of the Liver criteria. Multivariable Cox proportion…

AdultLiver CirrhosisMalemedicine.medical_specialtyPediatricsCarcinoma HepatocellularCirrhosisAdolescentmedicine.medical_treatmentCirrhosis Mortality Liver decompensation CohortLiver transplantationEsophageal and Gastric VaricesSeverity of Illness IndexYoung AdultSeverity of illnessmedicineHumansProspective StudiesYoung adultIntensive care medicineProspective cohort studyHepatic encephalopathyAgedProportional Hazards ModelsAged 80 and overFirst episodeHepatologybusiness.industryLiver NeoplasmsGastroenterologyAscitesMiddle Agedmedicine.diseaseLiver TransplantationAdolescent; Adult; Aged; Aged 80 and over; Ascites; Carcinoma Hepatocellular; Esophageal and Gastric Varices; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; Humans; Italy; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Prospective Studies; Severity of Illness Index; Young AdultItalyCirrhosisHepatic EncephalopathyMultivariate AnalysisCohortFemaleGastrointestinal HemorrhagebusinessLiver FailureFollow-Up Studies
researchProduct

Reappraisal of prognostic value of MELD-Na score: A new tool for liver transplant prioritization in HCV-infected patients

2014

Prioritizationmedicine.medical_specialtyHepatologybusiness.industryGastroenterologymedicineIntensive care medicinebusinessValue (mathematics)Digestive and Liver Disease
researchProduct

Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A…

2010

The incidence of de novo development of esophageal varices (EV) in patients with compensated liver cirrhosis has been determined by few studies in the short term and never in the long term. The aims of the present study were to determine the incidence and the risk factors associated with the development of EV and to assess whether antiviral treatment and achievement of sustained virologic response (SVR) may prevent de novo EV development in patients with HCV-induced cirrhosis. We studied 218 patients with compensated EV-free, HCV-induced cirrhosis consecutively enrolled between 1989 and 1992 at three referral centers in Milan, Italy. Endoscopic surveillance was performed at 3-year intervals…

Liver CirrhosisMalemedicine.medical_specialtyCarcinoma HepatocellularCirrhosisEsophageal and Gastric VaricesAntiviral AgentsGastroenterologyLiver diseaseEsophageal varicesRisk FactorsInternal medicinemedicineHumansProspective StudiesProspective cohort studyAgedHepatologybusiness.industryIncidenceLiver NeoplasmsHazard ratiovirus diseasesHepatitis CHepatitis C ChronicMiddle AgedHepatologymedicine.diseasedigestive system diseasesDiscontinuationItalyFemalebusinessFollow-Up StudiesCirrhosis HCV
researchProduct

Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals

2018

Background: Despite the dramatic improvement in viral eradication rates that has been reached with direct antiviral agents (DAAs),the real benefit of viral eradication after DAAs on hepatocellular carcinoma (HCC) development is still controversial. Aim: To prospectively assess the risk of HCC occurrence and early recurrence in a large cohort of DAAtreated HCV-cirrhotic patients and to identify potential predictors of HCC development. Methods: We analyzed data prospectively collected from 1927 consecutive HCV-infected cirrhotic patients treated with DAA from January to December 2015 in 10 tertiary liver centers in Italy and followed-up for one year after therapy. 161 patients had a previous …

Liver CirrhosisMaleCirrhosisSustained Virologic ResponseHepatocellular carcinomaDirect antiviral agentsDIRECT ACTING ANTIVIRALSGastroenterologyCohort Studies0302 clinical medicineRisk FactorsChronicIncidence (epidemiology)Liver NeoplasmsGastroenterologyMiddle AgedHepatitis CTumor recurrenceCirrhosis; Direct antiviral agents; HCV; Hepatocellular carcinoma; Aged; Antiviral Agents; Carcinoma Hepatocellular; Cohort Studies; Disease Progression; Female; Hepatitis C Chronic; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence Local; Risk Factors; alpha-Fetoproteins; Sustained Virologic ResponseItalyLocalCirrhosis030220 oncology & carcinogenesisHepatocellular carcinomaHCVDisease ProgressionPortal hypertension030211 gastroenterology & hepatologyFemalealpha-FetoproteinsCohort studymedicine.medical_specialtyCarcinoma HepatocellularEarly RecurrenceAntiviral Agents03 medical and health sciencesInternal medicinemedicineHumansneoplasmsAgedCirrhosiHepatologybusiness.industryCarcinomaHepatocellularHepatitis C Chronicmedicine.diseasedigestive system diseasesNeoplasm RecurrenceDirect antiviral agentNeoplasm Recurrence LocalCirrhosis; Direct antiviral agents; HCV; Hepatocellular carcinomabusiness
researchProduct

Smoking as a cofactor for causation of chronic pancreatitis: a meta-analysis.

2010

Objectives To assess the evidence for tobacco smoking as a risk factor for the causation of chronic pancreatitis. Methods We performed a meta-analysis with random-effects models to estimate pooled relative risks (RRs) of chronic pancreatitis for current, former, and ever smokers, in comparison to never smokers. We also performed dose-response, heterogeneity, publication bias, and sensitivity analyses. Results Ten case-control studies and 2 cohort studies that evaluated, overall, 1705 patients with chronic pancreatitis satisfied the inclusion criteria. When contrasted to never smokers, the pooled risk estimates for current smokers was 2.8 (95% confidence interval [CI], 1.8-4.2) overall and 2…

medicine.medical_specialtyAlcohol DrinkingEndocrinology Diabetes and Metabolismmedicine.medical_treatmentRisk AssessmentEndocrinologyRisk FactorsInternal medicinePancreatitis ChronicInternal MedicinemedicineOdds RatioHumansRisk factorHepatologybusiness.industrySmokingOdds ratiomedicine.diseaseConfidence intervalSurgerysmoking chronic pancreatitisRelative riskSmoking cessationPancreatitisRisk assessmentbusinessCohort study
researchProduct

Predicting Mortality Risk in Patients With Compensated HCV-Induced Cirrhosis: A Long-Term Prospective Study

2009

OBJECTIVES: The identification of prognostic factors associated with mortality is crucial in any clinical setting. METHODS: We enrolled in a prospective study 352 patients with compensated hepatitis C virus (HCV)-induced cirrhosis, consecutively observed between 1989 and 1992. At entry, patients underwent upper endoscopy to detect esophageal varices, and were then surveilled by serial clinical and ultrasonographic examination. The model for end-stage liver disease (MELD) score was calculated with information collected at enrollment. Baseline predictors and intercurrent events associated with mortality were assessed using the Cox regression model. RESULTS: During a median follow-up of 14.4 y…

AdultLiver CirrhosisMalemedicine.medical_specialtyTime FactorsCirrhosisBiopsy Fine-NeedleKaplan-Meier EstimateEsophageal and Gastric VaricesAntiviral AgentsRisk AssessmentSeverity of Illness IndexGastroenterologyCohort StudiesPredictive Value of TestsCause of DeathInternal medicineEpidemiologyConfidence IntervalsmedicineHumansProspective StudiesRisk factorProspective cohort studyAgedProbabilityProportional Hazards ModelsCause of deathSettore MED/12 - GastroenterologiaHepatologybusiness.industryGastroenterologyInterferon-alphavirus diseasesHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseImmunohistochemistrySurvival Analysisliver cirrhosis natural historyDisease ProgressionFemalebusinessRisk assessmentLiver FailureFollow-Up StudiesCohort studyThe American Journal of Gastroenterology
researchProduct